Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,500 shares, a decline of 90.7% from the February 28th total of 16,100 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 45,700 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.

Cocrystal Pharma Stock Performance

Shares of COCP stock traded up $0.02 during trading hours on Wednesday, hitting $1.50. 8,184 shares of the company were exchanged, compared to its average volume of 29,361. Cocrystal Pharma has a fifty-two week low of $1.35 and a fifty-two week high of $3.26. The company has a 50 day simple moving average of $1.83 and a two-hundred day simple moving average of $1.93. The firm has a market cap of $15.26 million, a P/E ratio of -0.81 and a beta of 2.35.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.